IBIS 10 mg ORALLY DISPERSIBLE TABLETS

2. What you need to know before taking Ibis

Do not take Ibis:

• if your child is allergic to bilastine or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to take Ibis if your child has moderate or severe kidney or liver impairment, low blood levels of potassium, magnesium, or calcium, if your child has or has had heart rhythm problems or if their heart rate is very low, if your child is taking medicines that may affect the heart rhythm, if your child has or has had a certain abnormal heart rhythm pattern (known as QTc interval prolongation in the electrocardiogram) that may occur in some types of heart disease, or if your child is taking other medicines (see "Using Ibis with other medicines").

Children

Do not give this medicine to children under 2 years of age or with a body weight below 15 kg, as there is not enough data available.

Using Ibis with other medicines

Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines, including those obtained without a prescription.

Some medicines should not be taken together, and others may require a dose adjustment when taken together.

Always tell your doctor or pharmacist if your child is taking or receiving any of the following medicines in addition to Ibis:

• Ketoconazole (an antifungal medicine)
• Erythromycin (an antibiotic)
• Diltiazem (for treating angina pectoris - chest pain or pressure)
• Ciclosporin (to reduce the activity of the immune system, and thus prevent transplant rejection or reduce disease activity in autoimmune and allergic disorders, such as psoriasis, atopic dermatitis, or rheumatoid arthritis)
• Ritonavir (for treating HIV)
• Rifampicin (an antibiotic)

Taking Ibis with food, drinks, and alcohol

These orodispersible tablets should notbe taken with food or withgrapefruit juice or other fruit juices, as this would decrease the effect of bilastine. To avoid this, you can:

• give your child the orodispersible tablet and wait for one hour before your child eats or takes fruit juices, or
• if your child has taken food or fruit juices, wait for two hours before giving the orodispersible tablet.

Bilastine, at the recommended dose in adults (20 mg), does not increase the sleepiness caused by alcohol.

Pregnancy, breastfeeding, and fertility

This medicine is for use in children from 2 to 11 years of age with a minimum body weight of 15 kg. However, the following information on the safe use of this medicine should be taken into account. There are no data or limited data available on the use of bilastine in pregnant or breastfeeding women and on its effects on fertility.

If you are pregnant or breastfeeding, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Consult your doctor or pharmacist before taking any medicine.

Driving and using machines

It has been shown that bilastine 20 mg does not affect performance during driving in adults. However, each patient's response to the medicine may be different. Therefore, check how this medicine affects your child before they ride a bicycle or other vehicles or operate machinery.

Ibis contains ethanol and sodium

This medicine contains 0.0015 mg of alcohol (ethanol) per orodispersible tablet, equivalent to 1 mg/100 g (0.001% w/w). The amount in one orodispersible tablet is equivalent to less than 0.00004 ml of beer or 0.00002 ml of wine.

The small amount of alcohol in this medicine does not produce any noticeable effect.

This medicine contains less than 1 mmol of sodium (23 mg) per orodispersible tablet; this is essentially "sodium-free".

3. How to take Ibis

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Use in children

The recommended dose in children from 2 to 11 years of age with a minimum body weight of 15 kg is 10 mg of bilastine (1 orodispersible tablet) once daily for the symptomatic relief of allergic rhinoconjunctivitis and urticaria.

Do not give this medicine to children under 2 years of age or with a body weight below 15 kg, as there is not enough data available.

For adults, including elderly patients and adolescents from 12 years of age, the recommended dose is 20 mg of bilastine once daily. For this patient population, a more suitable pharmaceutical form - tablets - is available; consult your doctor or pharmacist.

• The orodispersible tablet is for oral use.
• Please place the orodispersible tablet in your child's mouth. It will disperse rapidly in the saliva and can then be swallowed easily.
• Alternatively, you can disperse the orodispersible tablet in a spoonful of water before giving it to your child. This is highly recommended in children under 6 years, as they are prone to choking on tablets. Make sure there are no sediment remains in the spoon.
• You should use only water for dispersion;do not use grapefruit juice or any other fruit juice.
• You should give the orodispersible tablet to your child one hour before or two hours after they have taken any food or fruit juice.

The duration of treatment depends on your child's underlying disease, and your doctor will determine how long they should take Ibis.

If your child takes more Ibis than they should

If your child, or anyone else, exceeds the dose of this medicine, inform your doctor immediately or go to the casualty department of the nearest hospital. Please remember to take this medicine pack or this leaflet with you.

If your child forgets to take Ibis

If you forget to give your child their daily dose on time, give it to them the same day as soon as you remember. Then, give the next dose the following day at the usual time, as indicated by your doctor.

Never give a double dose to make up for a forgotten dose.

If your child stops taking Ibis

In general, no effects will appear after stopping treatment with Ibis.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If your child experiences allergic reactions whose symptoms may include difficulty breathing, dizziness, collapse, or loss of consciousness, swelling of the face, lips, tongue, or throat, and/or swelling and redness of the skin, stop giving this medicine and go to your doctor immediately.

Other side effects that may appear in children:

Common: may affect up to 1 in 10 people

• allergic conjunctivitis (eye irritation)
• headache

Uncommon: may affect up to 1 in 100 people

• eye irritation
• dizziness
• loss of consciousness
• diarrhea
• nausea (feeling sick)
• lip swelling
• eczema
• urticaria (hives)
• fatigue
• rhinitis (nasal irritation)
• stomach pain (abdominal pain/upper abdominal pain)

Side effects that may appear in adults and adolescents:

Common: may affect up to 1 in 10 people

• headache
• drowsiness

Uncommon: may affect up to 1 in 100 people

• electrocardiogram changes
• blood tests showing changes in liver function
• dizziness
• stomach pain
• fatigue
• increased appetite
• irregular heartbeat
• weight gain
• nausea (feeling sick)
• anxiety
• dry or irritated nose
• abdominal pain
• diarrhea
• gastritis (inflammation of the stomach lining)
• vertigo (a feeling of dizziness or spinning)
• feeling weak
• thirst
• shortness of breath
• dry mouth
• indigestion
• itching
• cold sore (herpes labialis)
• fever
• tinnitus (ringing in the ears)
• difficulty sleeping
• blood tests showing changes in kidney function
• increased blood fats

Frequency not known: cannot be estimated from the available data

• palpitations (feeling the heartbeat)
• tachycardia (fast heartbeat)
• vomiting

Reporting of side effects

If your child experiences any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's (AEMPS) online system: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Ibis

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the pack and blister after EXP. The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy, or take it to a designated collection point. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and further information

Composition of Ibis

• The active substance is bilastine. Each orodispersible tablet contains 10 mg of bilastine.
• The other ingredients are mannitol (E421), croscarmellose sodium, sodium stearyl fumarate, and sucralose (E955), red grape flavor (main components: gum arabic, ethyl butyrate, triacetin, methyl anthranilate, ethanol, d-limonene, linalool).

Appearance and packaging

Ibis 10 mg orodispersible tablets are round, slightly biconvex, and white, with a diameter of 8 mm.

The tablets are packaged in blisters of 10, 20, 30, or 50 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Menarini International Operations Luxembourg, S.A.

1, Avenue de la Gare

L-1611 Luxembourg

Manufacturer

Faes Farma, S.A.

Maximo Agirre Kalea, 14

48940 Leioa (Bizkaia)

Spain

or

A.Menarini Manufacturing Logistics and Services S.r.l.

Campo di Pile

L’Aquila

Italy

You can obtain further information on this medicine from the local representative of the marketing authorization holder:

Laboratorios Menarini, S.A.

Alfons XII, 587 – E 08918 Badalona

(Barcelona) T. +34 934 628 800

E-mail: [email protected]

This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Austria: Nasitop 10 mg Schmelztabletten

Belgium: Bellozal 10 mg orodispersible tablets

Bulgaria: ???????? ?? ???? 10 mg ???????????? ?? ? ?????? ????????

Cyprus: Bilaz 10 mg δισκ?α διασπειρ?μενα στο στ?μα

Czech Republic: Xados

Denmark: Revitelle, smeltetabletter 10 mg

Estonia: Opexa

Finland: Revitelle

France: Bilaska 10 mg comprimé orodispersible

Germany: Bilaxten 10 mg Schmelztabletten

Greece: Bilaz 10 mg δισκ?α διασπειρ?μενα στο στ?μα

Hungary: Lendin

Iceland: Bilaxten 10 mg munndreifitöflur

Ireland: Drynol

Latvia: Opexa 10 mg mute dispergejamas tabletes

Lithuania: Opexa

Luxembourg: Bellozal 10 mg orodispersible tablets

Malta: Gosall 10 mg orodispersible tablets

Norway: Zilas 10 mg smeltetablett

Poland: Clatra

Portugal: Lergonix 10 mg comprimido orodispersível

Romania: Borenar 10 mg comprimate orodispersabile

Slovakia: Omarit 10 mg orodispergovatelné tablety

Slovenia: Bilador 10 mg orodispersibilne tablete

Spain: Ibis 10 mg comprimidos bucodispersables

Sweden: Bilaxten

United Kingdom (Northern Ireland): Ilaxten

Date of last revision of this leaflet:March 2025

Detailed information on this medicine is available on the website of the Spanish Medicines and Healthcare Products Agency (AEMPS) (http://www.aemps.gob.es/)